Europe's top psychedelic startups to watch, according to investors
Europe’s psychedelic sector is becoming increasingly mainstream, here are the top startups in the space, according to investors
Source: sifted.eu
📰 Compass Pathways News
Page 24 - Compass Pathways News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Compass Pathways. Real-time updates on events, politics, business and more.
Why Compass Pathways Stock Blasted Higher This Week
Wall Street is growing increasingly bullish about the drugmaker's prospects.
Source: fool.com
3 Stocks to Buy and Hold for the Long Term
Here's why OrthoPediatrics, Compass Pathways, and Nano-X Imaging look like great stocks.
George Budwell Patrick Bafuma Orthopediatrics Taylor Carmichael Nano Sk Telecom World Health Organization Drug Administration
Source: fool.com
Psychedelics and mental health: What to know.
Compass Pathways and other companies are investing in research on psychedelic drugs, hoping to treat conditions like PTSD, anxiety, and depression.
Source: slate.com
Health Canada Grants MDMA Production and Distribution
CEO says licensing amendment positions Optimi to be a “global leader in the safe supply of EU-GMP Psilocybin, MDMA, and other psychedelics”...
Source: globenewswire.com
SBIO Rallies on M&A Announcements
The ALPS Medical Breakthroughs ETF (SBIO) rallied 14.53% last week, propelled by positive earnings and two significant M&A announcements in the portfolio.
Day One Biopharmaceuticals Inc Global Blood Therapeutics Inc Compass Pathways Inc Allovir Inc Pfizer Inc Amgen Inc
Source: etftrends.com
Investegate |COMPASS Pathways Announcements | COMPASS Pathways: COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
Investegate announcements from COMPASS Pathways, COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
Source: investegate.co.uk
COMPASS Pathways plc announces second quarter 2022
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Highlights: Kabir Nath appointed as Chief Executive Officer       Phase III program submitted to FDA...
New York United States Columbia University United Kingdom City Of University Of California San Diego
Source: globenewswire.com
COMPASS Pathways launches phase II clinical trial of
Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which...
Source: globenewswire.com
Investegate |COMPASS Pathways Announcements | COMPASS Pathways: COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
Investegate announcements from COMPASS Pathways, COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
Source: investegate.co.uk